Paper · 40487598
Therapeutic effectiveness of intratympanic and retroauricular methylprednisolone sodium succinate for refractory sudden sensorineural hearing loss in diabetic patients.
Li D and 7 others. World J Diabetes, 2025. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Therapeutic effectiveness of intratympanic and retroauricular methylprednisolone sodium succinate for refractory sudden sensorineural hearing loss in diabetic patients. Papers, record 40487598. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40487598
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic effectiveness of intratympanic and retroauricular methylprednisolone sodium succinate for refractory sudden sensorineural hearing loss in diabetic patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,866,519 | Postauricular injection of methylprednisolone sodium succinate as a salvage treatment for refractory sudden sensorineural hearing loss. | Ir J Med Sci | 2021 | https://conductscience.org/library/papers/33866519 | PubMed |
| 2 | 35,863,163 | Is postauricular injection a systemic or a topical route for inner ear drug delivery? | Hear Res | 2022 | https://conductscience.org/library/papers/35863163 | PubMed |
| 3 | 31,939,327 | Research progress in refractory sudden hearing loss: steroid therapy. | J Int Med Res | 2020 | https://conductscience.org/library/papers/31939327 | PubMed |
| 4 | 38,251,843 | Salvage therapy for refractory sudden sensorineural hearing loss (RSSNHL): a systematic review and network meta-analysis. | Int J Audiol | 2025 | https://conductscience.org/library/papers/38251843 | PubMed |
| 5 | 35,916,897 | [Tolerance and acceptance of intratympanic injections]. | HNO | 2022 | https://conductscience.org/library/papers/35916897 | PubMed |
| 6 | 39,345,079 | Analysis of Therapeutic Options for Noise-Induced Hearing Loss: Retroauricular Injection of Methylprednisolone Sodium Succinate Combined with Hyperbaric Oxygenation. | Noise Health | 2024 | https://conductscience.org/library/papers/39345079 | PubMed |
| 7 | 20,362,815 | Sudden sensorineural hearing loss. | Lancet | 2010 | https://conductscience.org/library/papers/20362815 | PubMed |
| 8 | 38,983,415 | Therapeutic efficacy of methylprednisolone sodium succinate via diverse administration routes for mid- to high-frequency sudden sensorineural hearing loss. | World J Clin Cases | 2024 | https://conductscience.org/library/papers/38983415 | PubMed |
| 9 | 36,908,605 | Diagnosis, differential diagnosis, and treatment for sudden sensorineural hearing loss: Current otolaryngology practices in China. | Front Neurol | 2023 | https://conductscience.org/library/papers/36908605 | PubMed |
| 10 | 23,959,817 | Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. | Otolaryngol Head Neck Surg | 2013 | https://conductscience.org/library/papers/23959817 | PubMed |
1 to 10 of 33
See all 33 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,979,094 | Efficacy and safety of local vs. systemic steroid therapy for patients with sudden deafness and diabetes mellitus: A systematic review and meta-analysis. | Biomed Rep | 2026 | https://conductscience.org/library/papers/42979094 | PubMed |
| 42,840,132 | Methylprednisolone sodium succinate combined with azithromycin in the treatment of Mycoplasma pneumonia in children and Its effect on immune function. | Front Pediatr | 2026 | https://conductscience.org/library/papers/42840132 | PubMed |
| 41,838,149 | Efficacy of multimodal therapy for sudden sensorineural hearing loss: a propensity score-matched analysis of 1632 patients. | Eur Arch Otorhinolaryngol | 2026 | https://conductscience.org/library/papers/41838149 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1,401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| IL6 | 3,569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40487598
GET https://conductscience.org/api/papers/v1/40487598/references?page=2